ANYVERSE SL

Their core work

ANYVERSE SL is a Madrid-based technology SME specialising in simulation and visualisation software. Their participation in first.stage points to core capabilities in real-time previsualisation tools aimed at creative professionals — artists, directors, and designers who need fast, accurate scene previews before committing to costly production. Their subsequent involvement as a third party in RAINBOW, a biomechanics simulation project for personalised clinical design, reveals that the same underlying simulation engine is extensible to scientific and medical domains. The company's website (nextlimit.com) connects them to the Next Limit Technologies ecosystem, known for physically-based fluid and rendering simulation tools widely used across visual effects and engineering industries.

What they specialise in

How they've shifted over time

ANYVERSE entered H2020 through the digital creative industries, contributing visualisation and previsualisation tooling to support artists and production teams (first.stage, 2016). By 2018 they had expanded — or been brought in — to a biomedical research project (RAINBOW) applying rapid simulation to clinical design problems. With only two projects and no keyword data available, this trajectory is suggestive rather than conclusive, but the pattern fits a company that built a simulation engine for entertainment and is now testing its value in adjacent high-value verticals. Whether the clinical direction represents a deliberate strategic pivot or a one-off collaboration is unclear from the available data alone.

ANYVERSE appears to be moving its core simulation technology toward scientific and clinical applications, which could make them a relevant contributor to future digital health or medical device design consortia.

How they like to work

ANYVERSE has never led an H2020 project — they enter consortia as a participant or third party, contributing specific software capabilities rather than overall project direction. Despite a small project count, they have accumulated 22 distinct consortium partners across 7 countries, which suggests their technology is seen as a useful modular addition to diverse team compositions. This profile is typical of a specialist software provider that is brought in to solve a defined technical sub-problem, not to shape research strategy.

ANYVERSE has collaborated with 22 unique partners spanning 7 countries across its two projects — a broader network than its small funding total might suggest. No geographic concentration is evident from the data, pointing to cross-European engagement rather than a regional cluster focus.

What sets them apart

ANYVERSE occupies an unusual niche: a simulation software SME whose tools originated in high-end visual effects and are now being tested in clinical and scientific research settings. Few companies can credibly bridge physically-based rendering for creative workflows and rapid biomechanics simulation for medical device design. For a consortium needing real-time 3D simulation or visualisation expertise without building it in-house, they offer a ready-made, commercially developed toolset that academic partners typically cannot replicate.

Highlights from their portfolio

• first.stage
  The only project where ANYVERSE received direct EC funding (EUR 151,338), positioning them as a full participant in a digital tools project targeting the creative industries — their primary commercial domain.
• RAINBOW
  Demonstrates a significant domain leap: contributing simulation technology to a biomedical project on personalised clinical design, showing the breadth of their software's application potential.